Skip to main content
HCPCS Q2058 · Level II · Part B drug

HCPCS Q2058: Obecabtagene autoleucel, 10 up to 400 million cd19 car-positive viable t cells,

Reviewed by QuickIntell RCM Editorial Team · Last reviewed

Data effective
Data currency: ASP payment limits October 2026 (effective October 1, 2026); MUE and NCCI edits 2026 Q4 (effective October 1, 2026); OPPS Addendum B July 2026 (effective July 1, 2026). Next CMS release: January 1, 2027 (ASP, MUE, NCCI and OPPS quarterly updates).

Key facts for Q2058

Billing unit
Per Therapeutic Dose
Obecbtge autol up to 400 mil
ASP payment limit
$293,725.702
October 2026
Practitioner MUE
1
MAI 2
OPPS status
SI G
APC 0831
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS Q2058 is the Level II code for Obecabtagene autoleucel, 10 up to 400 million cd19 car-positive viable t cells,, billed per Per Therapeutic Dose. The Medicare Part B ASP payment limit for October 2026 is $293,725.702 per billing unit. The practitioner MUE allows up to 1 units per date of service (MAI 2). Under OPPS it carries status indicator G in APC 0831. Q2058 is billed in units of Per Therapeutic Dose; the quantity administered, the NDC package and the units on the claim must reconcile, which is the check that prevents CARC 16 and 151 returns on this line. The ASP crosswalk maps 1 NDC to it, sold as Aucatzyl by Autolus, Inc. No current Billing and Coding Article lists Q2058, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for Q2058 at $293,725.702 per Per Therapeutic Dose for October 2026, derived from manufacturer average sales price plus 6%. Beneficiary coinsurance is 20%.

ASP payment limits for Q2058
QuarterPayment limitPerCoinsurance
October 2026$293,725.702Per Therapeutic Dose20%
July 2026n/aPer Therapeutic Dose—
CMS note: Added October 2026 - Inflation-adjusted coinsurance

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 1 NDC from 1 labeler to Q2058. Report the NDC in the claim's drug segment and bill the number of Q2058 units that equals the quantity administered divided by Per Therapeutic Dose; the last column gives units per full package.

NDCs that crosswalk to Q2058
NDCDrug nameLabelerPackage sizeBilling units / package
83047-0410-04AucatzylAutolus, Inc1 × 12

Medically Unlikely Edits (MUE)

CMS publishes 2 MUE values for Q2058. For practitioners the limit is 1 unit per date of service with adjudication indicator 2, a date-of-service policy edit: the limit reflects CMS policy and units above it deny even if split across lines; appeals rarely succeed.

MUE values for Q2058 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services12 Date of Service Edit: PolicyCode Descriptor / CPT Instruction
Facility outpatient hospital12 Date of Service Edit: PolicyCode Descriptor / CPT Instruction

NCCI edits and add-on relationships

No active practitioner PTP pair lists Q2058 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

Q2058 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists Q2058 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the July 2026 OPPS Addendum B, Q2058 carries status indicator G and is assigned to APC 0831, with a published national unadjusted payment of $278,250.00. Status G marks pass-through drug payment, which is time-limited.

Common denials for Q2058 and how to prevent them

CARC 16 · M119

NDC missing, invalid or not matched to the HCPCS code

CARC 151 · N362

units billed exceed the MUE for the date of service

CARC 50 · N115

diagnosis not covered by the applicable coverage article or LCD

How QuickIntell checks Q2058 before the claim leaves

QuickCode validates the NDC-to-unit conversion against the current ASP crosswalk, checks units against every published MUE setting and flags PTP and add-on conflicts on the same claim. QuickRCM routes CARC 16, 151 and 50 denials on drug lines with the matching coverage article attached so the appeal starts with evidence.

Explore QuickCodeExplore QuickRCMBook a demo

Frequently asked questions — HCPCS Q2058

What does HCPCS code Q2058 describe?

Q2058 is defined by CMS as "Obecabtagene autoleucel, 10 up to 400 million cd19 car-positive viable t cells,". Each billing unit represents Per Therapeutic Dose, so the units reported on the claim must equal the dose administered divided by that unit.

What is the Medicare reimbursement for Q2058 in October 2026?

The ASP-based payment limit is $293,725.702 per Per Therapeutic Dose, with 20% beneficiary coinsurance. Medicare Administrative Contractors apply this limit; commercial payers use their own fee schedules.

How many units of Q2058 can be billed per day?

The practitioner Medically Unlikely Edit is 1 units per date of service with adjudication indicator 2 (2 Date of Service Edit: Policy). MAI 2 edits are policy limits and are rarely overturned on appeal. CMS cites "Code Descriptor / CPT Instruction" as the rationale.

Which NDCs map to Q2058?

The October 2026 ASP crosswalk lists 1 NDC from 1 labeler: Aucatzyl (Autolus, Inc). For example NDC 83047-0410-04 is a 1 package equal to 2 billing units. The crosswalk's billing-units-per-package figure converts each package into Q2058 units.

Does Q2058 have NCCI bundling edits?

No active practitioner PTP pairs list Q2058 as a column-1 or column-2 code in the v323r0 release. Unit limits (MUE) and medical-necessity coverage rules still apply.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-10-01. Verify against the primary file before billing or contracting decisions.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B and the Medicare Coverage Database. Payment limits are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.